BR112018009281A2 - composições para tratar atrofia muscular espinhal - Google Patents
composições para tratar atrofia muscular espinhalInfo
- Publication number
- BR112018009281A2 BR112018009281A2 BR112018009281A BR112018009281A BR112018009281A2 BR 112018009281 A2 BR112018009281 A2 BR 112018009281A2 BR 112018009281 A BR112018009281 A BR 112018009281A BR 112018009281 A BR112018009281 A BR 112018009281A BR 112018009281 A2 BR112018009281 A2 BR 112018009281A2
- Authority
- BR
- Brazil
- Prior art keywords
- compositions
- muscular atrophy
- spinal muscular
- treating spinal
- compound
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 208000002320 spinal muscular atrophy Diseases 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hospice & Palliative Care (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
a presente invenção oferece composições farmacêuticas compreendendo um composto de fórmula (i) (i) onde a, r1, r2 e r3 são como descritos neste pedido, assim como sais farmaceuticamente aceitáveis do mesmo. ademais, a presente invenção refere-se à produção das composições farmacêuticas compreendendo um composto de fórmula (i) e seu uso como medicamentos.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP15194297 | 2015-11-12 | ||
EP15194297.6 | 2015-11-12 | ||
PCT/EP2016/076905 WO2017080967A1 (en) | 2015-11-12 | 2016-11-08 | Compositions for treating spinal muscular atrophy |
Publications (3)
Publication Number | Publication Date |
---|---|
BR112018009281A2 true BR112018009281A2 (pt) | 2018-11-06 |
BR112018009281A8 BR112018009281A8 (pt) | 2019-02-26 |
BR112018009281B1 BR112018009281B1 (pt) | 2023-10-31 |
Family
ID=54542056
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112018009281-9A BR112018009281B1 (pt) | 2015-11-12 | 2016-11-08 | Composições para tratar atrofia muscular espinhal e seu uso |
Country Status (14)
Country | Link |
---|---|
US (2) | US20180289712A1 (pt) |
EP (2) | EP4360707A2 (pt) |
JP (1) | JP6659841B2 (pt) |
KR (1) | KR102162062B1 (pt) |
CN (1) | CN108289959B (pt) |
AR (1) | AR106717A1 (pt) |
AU (1) | AU2016353961B2 (pt) |
BR (1) | BR112018009281B1 (pt) |
CA (1) | CA3002494C (pt) |
EA (1) | EA036399B1 (pt) |
HK (1) | HK1256089A1 (pt) |
IL (1) | IL258497B (pt) |
MX (1) | MX2018005890A (pt) |
WO (1) | WO2017080967A1 (pt) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
MX371050B (es) | 2014-05-15 | 2020-01-14 | Hoffmann La Roche | Compuestos para tratar atrofia muscular espinal. |
CN108289959B (zh) | 2015-11-12 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的组合物 |
CN108697709A (zh) | 2015-12-10 | 2018-10-23 | Ptc医疗公司 | 用于治疗亨廷顿病的方法 |
JP6872550B2 (ja) | 2015-12-10 | 2021-05-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | 架橋されたピペリジン誘導体 |
WO2018073141A1 (en) * | 2016-10-18 | 2018-04-26 | F. Hoffmann-La Roche Ag | New composition for treating sma |
WO2018226622A1 (en) | 2017-06-05 | 2018-12-13 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
CA3067592A1 (en) | 2017-06-28 | 2019-01-03 | Ptc Therapeutics, Inc. | Methods for treating huntington's disease |
EP3644996B1 (en) | 2017-06-28 | 2023-07-26 | PTC Therapeutics, Inc. | Methods for treating huntington's disease |
SG11202000980QA (en) | 2017-08-04 | 2020-02-27 | Skyhawk Therapeutics Inc | Methods and compositions for modulating splicing |
KR20230020580A (ko) * | 2017-09-22 | 2023-02-10 | 에프. 호프만-라 로슈 아게 | 7-(4,7-다이아자스피로[2.5]옥탄-7-일)-2-(2,8-다이메틸이미다조[1,2-b]피리다진-6-일)피리도[1,2-a]피리미딘-4-온 유도체의 제조 방법 |
AU2018344402A1 (en) | 2017-10-03 | 2020-04-09 | F. Hoffmann-La Roche Ag | New treatment of SMA |
CN112135815A (zh) | 2018-03-27 | 2020-12-25 | Ptc医疗公司 | 用于治疗亨廷顿氏病的化合物 |
US11685746B2 (en) | 2018-06-27 | 2023-06-27 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating Huntington's disease |
CA3103976A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heterocyclic and heteroaryl compounds for treating huntington's disease |
AU2019293757B2 (en) * | 2018-06-27 | 2022-09-15 | Reborna Biosciences, Inc. | Prophylactic or therapeutic agent for spinal muscular atrophy |
EP3867256A1 (en) * | 2018-10-19 | 2021-08-25 | F. Hoffmann-La Roche AG | New forms of pyrido[1,2-a]pyrimidin-4-one derivatives, its formulation and its process of making |
JP2022521467A (ja) | 2019-02-05 | 2022-04-08 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
CN113677344A (zh) | 2019-02-06 | 2021-11-19 | 斯基霍克疗法公司 | 用于调节剪接的方法和组合物 |
WO2020249577A1 (en) | 2019-06-12 | 2020-12-17 | F. Hoffmann-La Roche Ag | New treatment of sma |
EP4013387A4 (en) * | 2019-08-15 | 2023-09-27 | Biogen MA Inc. | COMBINATION THERAPY FOR SPINAL MUSCLE ATROPHY |
CN118055767A (zh) | 2021-10-06 | 2024-05-17 | 豪夫迈·罗氏有限公司 | 新颖的组合施用 |
WO2023202501A1 (zh) * | 2022-04-18 | 2023-10-26 | 深圳市塔吉瑞生物医药有限公司 | 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1383409A (en) | 1972-09-09 | 1974-02-12 | Pfizer Ltd | Derivatives of 2-amino- and 4-amino-quinazoline and pharmaceutical compositions containing them |
US6774134B2 (en) | 2000-12-20 | 2004-08-10 | Bristol-Myers Squibb Company | Heterocyclic substituted 2-methyl-benzimidazole antiviral agents |
WO2004082581A2 (fr) * | 2003-03-11 | 2004-09-30 | Trophos | Application a titre de medicaments de derives de cholest-4-en-3- one, compositions pharmaceutiques les renfermant et nouveaux derives |
JP5384793B2 (ja) | 2003-12-24 | 2014-01-08 | バイオウタ サイエンティフィック マネジメント プロプライエタリー リミテッド | 呼吸器合胞体ウイルス感染の処置のための多環式薬剤 |
US20060153920A1 (en) | 2004-09-24 | 2006-07-13 | Ketan Amin | Lyophilized pharmaceutical compositions |
FR2914188B1 (fr) | 2007-03-28 | 2012-06-22 | Trophos | Nouvelle composition a base d'oxime de cholest-4-en-3-one |
US8633019B2 (en) | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
US8986935B2 (en) | 2008-08-13 | 2015-03-24 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
US8126566B2 (en) | 2008-08-14 | 2012-02-28 | Cardiac Pacemakers, Inc. | Performance assessment and adaptation of an acoustic communication link |
EP2359812A1 (en) | 2010-01-18 | 2011-08-24 | Cephalon France | Oral lyophilised compositions |
US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
US8871756B2 (en) | 2011-08-11 | 2014-10-28 | Hoffmann-La Roche Inc. | Compounds for the treatment and prophylaxis of Respiratory Syncytial Virus disease |
GB201119538D0 (en) | 2011-11-10 | 2011-12-21 | Viral Ltd | Pharmaceutical compounds |
KR102057351B1 (ko) | 2011-12-30 | 2019-12-18 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
CN104203239B (zh) * | 2012-01-26 | 2017-09-08 | Ptc医疗公司 | 用于治疗脊髓性肌萎缩的化合物 |
KR102137087B1 (ko) * | 2012-02-10 | 2020-07-24 | 피티씨 테라퓨틱스, 인크. | 척수성 근위축증을 치료하기 위한 화합물 |
EP2872493B1 (en) | 2012-07-13 | 2018-11-14 | Indiana University Research and Technology Corporation | 5,6,7-trimethoxy 4-phenyl quinolin-2-one derivatives for treatment of spinal muscular atrophy |
CA2910508A1 (en) | 2013-05-14 | 2014-11-20 | Song Feng | Aza-oxo-indoles for the treatment and prophylaxis of respiratory syncytial virus infection |
EP3013345B1 (en) | 2013-06-25 | 2017-11-22 | F. Hoffmann-La Roche AG | Compounds for treating spinal muscular atrophy |
AR099134A1 (es) | 2014-01-24 | 2016-06-29 | Hoffmann La Roche | Procedimiento para la preparación de n-[(3-aminooxetán-3-il)metil]-2-(1,1-dioxo-3,5-dihidro-1,4-benzotiazepín-4-il)-6-metil-quinazolín-4-amina |
MX371050B (es) * | 2014-05-15 | 2020-01-14 | Hoffmann La Roche | Compuestos para tratar atrofia muscular espinal. |
CN108289959B (zh) | 2015-11-12 | 2021-07-16 | 豪夫迈·罗氏有限公司 | 用于治疗脊髓性肌萎缩的组合物 |
-
2016
- 2016-11-08 CN CN201680066250.2A patent/CN108289959B/zh active Active
- 2016-11-08 EP EP24156739.5A patent/EP4360707A2/en active Pending
- 2016-11-08 AU AU2016353961A patent/AU2016353961B2/en active Active
- 2016-11-08 CA CA3002494A patent/CA3002494C/en active Active
- 2016-11-08 EA EA201891103A patent/EA036399B1/ru not_active IP Right Cessation
- 2016-11-08 JP JP2018524450A patent/JP6659841B2/ja active Active
- 2016-11-08 BR BR112018009281-9A patent/BR112018009281B1/pt active IP Right Grant
- 2016-11-08 KR KR1020187016504A patent/KR102162062B1/ko active Protection Beyond IP Right Term
- 2016-11-08 WO PCT/EP2016/076905 patent/WO2017080967A1/en active Application Filing
- 2016-11-08 EP EP16794290.3A patent/EP3373972B1/en active Active
- 2016-11-08 MX MX2018005890A patent/MX2018005890A/es unknown
- 2016-11-10 AR ARP160103436A patent/AR106717A1/es unknown
-
2018
- 2018-04-04 IL IL258497A patent/IL258497B/en unknown
- 2018-04-17 US US15/955,337 patent/US20180289712A1/en not_active Abandoned
- 2018-11-27 HK HK18115151.3A patent/HK1256089A1/zh unknown
-
2019
- 2019-11-15 US US16/685,431 patent/US11938136B2/en active Active
Also Published As
Publication number | Publication date |
---|---|
EA036399B1 (ru) | 2020-11-06 |
WO2017080967A1 (en) | 2017-05-18 |
EP3373972C0 (en) | 2024-03-20 |
EP3373972B1 (en) | 2024-03-20 |
MX2018005890A (es) | 2018-08-15 |
BR112018009281A8 (pt) | 2019-02-26 |
US11938136B2 (en) | 2024-03-26 |
EP3373972A1 (en) | 2018-09-19 |
CA3002494A1 (en) | 2017-05-18 |
HK1256089A1 (zh) | 2019-09-13 |
IL258497B (en) | 2021-07-29 |
US20180289712A1 (en) | 2018-10-11 |
AU2016353961B2 (en) | 2019-08-29 |
EA201891103A1 (ru) | 2018-11-30 |
CN108289959A (zh) | 2018-07-17 |
US20200323856A1 (en) | 2020-10-15 |
CA3002494C (en) | 2021-01-12 |
EP4360707A2 (en) | 2024-05-01 |
BR112018009281B1 (pt) | 2023-10-31 |
KR102162062B1 (ko) | 2020-10-07 |
AR106717A1 (es) | 2018-02-14 |
KR20180080317A (ko) | 2018-07-11 |
JP6659841B2 (ja) | 2020-03-04 |
CN108289959B (zh) | 2021-07-16 |
AU2016353961A1 (en) | 2018-04-26 |
IL258497A (en) | 2018-06-28 |
JP2018533605A (ja) | 2018-11-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112018009281A8 (pt) | composições para tratar atrofia muscular espinhal | |
CR20160518A (es) | Compuestos para tratar atrofia muscular espinal | |
CY1122046T1 (el) | Δικυκλικα ετεροκυκλικα παραγωγα ως αναστολεις βρομοτομεων | |
CO2017013708A2 (es) | Macrociclos peptídicos contra acinetobacter baumannii. | |
BR112018071216A2 (pt) | inibidores de bromodomínios | |
CO2018004857A2 (es) | Derivados de dihidroimidazopirazinona usados en el tratamiento del cáncer | |
BR112014018990A8 (pt) | Derivados de ácido benzotiazol-6-il acético e seu uso para tratamento de uma infecção | |
MX2015017345A (es) | Compuestos para tratar atrofia muscular espinal. | |
BR112018070123A2 (pt) | oxiesterós e métodos de uso dos mesmos | |
BR112016017996A2 (pt) | 6-heteroariloxi- or 6-ariloxi-quinolina-2-carboxamidas e método de uso | |
TW201613864A (en) | Novel compounds | |
CY1122077T1 (el) | Νεα δακτυλιωμενα φαινοξυακεταμιδια | |
CL2021001388A1 (es) | Compuestos útiles en la terapia para el vih | |
BR112017019653A2 (pt) | derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd | |
NZ734542A (en) | Hydroxyalkyl-piperazine derivatives as cxcr3 receptor modulators | |
DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas | |
EA201700356A1 (ru) | Новые циклопропанбензофуранилпиридопиразиндионы | |
EA201891319A1 (ru) | Соединения алкилдигидрохинолинсульфонамида | |
BR112015003998A2 (pt) | compostos de cianopirazol lpar-substituídos | |
BR112017021083A2 (pt) | piridopirimidinonas e seu uso como moduladores do receptor de nmda | |
EA202090978A1 (ru) | Новые макроциклические производные, способ их получения и содержащие их фармацевтические композиции | |
BR112019007631A2 (pt) | inibidores de bromodomínios | |
BR112018003181A2 (pt) | composto, composição, e, método para tratar infecção por hiv | |
BR112022005728A2 (pt) | Compostos de tiazol carboxamida e seu uso para o tratamento de infecções micobacterianas | |
BR112018002681A2 (pt) | ?composto, composição, e, método para tratamento de infecção por hiv? |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
B06A | Patent application procedure suspended [chapter 6.1 patent gazette] | ||
B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/11/2016, OBSERVADAS AS CONDICOES LEGAIS |